Zio XT ECG Monitoring System vs KardiaAI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by iRhythm Technologies
VS
by AliveCor

AI Verdict

Zio XT is a comprehensive, wearable ECG monitoring system providing continuous cardiac data acquisition and AI-powered analysis for up to 14 days. In contrast, KardiaAI is an FDA-cleared AI software library designed for integration into other ECG devices and platforms to provide medical-grade rhythm analysis. While both leverage AI for ECG interpretation, Zio XT offers a complete, end-to-end monitoring solution, whereas KardiaAI provides the analytical intelligence as a component for third-party systems.

Choose Zio XT ECG Monitoring System if…

Choose Zio XT if your primary need is extended, continuous cardiac monitoring for up to 14 days with minimal patient burden. This system is ideal for detecting intermittent arrhythmias that might be missed by shorter monitoring periods, offering a comfortable, water-resistant wearable biosensor with expert AI analysis and review.

View Zio XT ECG Monitoring System →

Choose KardiaAI if…

Choose KardiaAI if you require a powerful, FDA-cleared AI engine to integrate into your existing ECG devices, mobile applications, or web platforms for real-time rhythm analysis. This solution is best suited for developers and healthcare providers looking to enhance their own systems with medical-grade detection of various cardiac conditions like AFib, bradycardia, and tachycardia.

View KardiaAI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Zio XT ECG Monitoring System KardiaAI
Pricing Contact for pricing Subscription-based for advanced features and services.
Deployment Cloud-based (AWS EC2 platform), no on-premise hardware required. Mobile app, cloud-based.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio XT ECG Monitoring System

Zio XT is designed as a complete, patient-friendly wearable system with no external wires, water resistance, and high reported patient compliance and satisfaction. This makes it directly usable and comfortable for patients over extended periods. KardiaAI, as an API library, relies on integration into other devices for end-user usability, making its direct 'usability' less applicable in this head-to-head comparison.

Clinical Value

Zio XT ECG Monitoring System

Both tools are FDA-cleared and offer medical-grade accuracy for cardiac arrhythmia detection. However, Zio XT provides continuous monitoring for up to 14 days, which offers a significant clinical advantage for capturing intermittent and elusive arrhythmias, potentially leading to a higher diagnostic yield. While KardiaAI lists a broad range of specific detections, the continuous, long-duration monitoring of Zio XT provides a distinct edge in comprehensive diagnostic capability.

Pricing & Value

Zio XT ECG Monitoring System

Zio XT offers transparent, per-patient service pricing for its comprehensive diagnostic monitoring, with clear rates for the UK and US Medicare. This provides a straightforward value proposition for healthcare providers. KardiaAI's listed pricing is for consumer subscriptions, and specific enterprise pricing for its AI library integration is not provided, making a direct comparison for enterprise value challenging.

Enterprise Readiness

Zio XT ECG Monitoring System

Both tools are FDA-cleared, HIPAA compliant, and offer BAAs, indicating foundational enterprise readiness. Zio XT, as a cloud-based system requiring no on-premise hardware, presents a more 'ready-to-deploy' solution for healthcare enterprises. KardiaAI, being an API library, offers flexibility but necessitates additional integration and development effort from the adopting enterprise.

Innovation

Tie

Both tools demonstrate significant innovation in cardiac AI, albeit in different areas. Zio XT innovates in the holistic delivery of long-term, patient-friendly continuous monitoring with advanced AI for comprehensive diagnostics. KardiaAI's innovation lies in the breadth and modularity of its medical-grade AI algorithms, offering a versatile library for integration into various devices and platforms.

Support & Docs

Tie

Both companies offer robust support and documentation tailored to their product models. iRhythm (Zio XT) provides extensive provider and patient support, including 24/7 assistance for billing and inventory management, along with comprehensive instructional manuals. AliveCor (KardiaAI) offers strong developer-focused support for its API/SDK integrations, including comprehensive technical documentation, an engaged engineering support team, and API documentation, which is crucial for its integration-centric nature.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Zio XT ECG Monitoring System KardiaAI
Product Name Zio XT ECG Monitoring System KardiaAI
Company iRhythm Technologies AliveCor
Core Functionality Wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis. FDA-cleared AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia.
Primary Form Factor / Delivery Wearable single-lead ECG biosensor (Zio biosensor) AI software library (API) for integration into other ECG devices and software.
Specific Detections / Analysis Arrhythmia detection and diagnosis (general). Atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE), ECG noise filtering, noisy ECG detection.
Maximum Monitoring Duration Up to 14 days of continuous monitoring. Not specified

Videos

Demos, reviews, and walkthroughs featuring Zio XT ECG Monitoring System and KardiaAI.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Zio XT is a complete wearable, single-lead ECG biosensor system that provides continuous ambulatory cardiac monitoring for up to 14 days, with data analyzed by FDA-cleared AI and expert review. KardiaAI, in contrast, is an FDA-cleared AI software library designed to analyze ambulatory ECG rhythms, detecting various cardiac conditions when integrated into other mobile apps and web platforms.
The Zio XT system offers continuous ambulatory cardiac monitoring for up to 14 days, capturing every heartbeat. KardiaAI is an AI software library for analyzing ambulatory ECG rhythms, but it does not specify a continuous monitoring duration as it is an analysis tool for ECGs from various devices.
Zio XT utilizes a proprietary, FDA-cleared deep-learned AI algorithm for general ECG data analysis and arrhythmia detection and diagnosis. KardiaAI's library detects atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, and Sinus Rhythm with Supraventricular Ectopy (SVE).
With Zio XT, patients can activate a button on the biosensor to log symptomatic events, although the device continuously records every heartbeat. For KardiaAI, patient interaction for event logging would depend on the specific ECG device or mobile application into which the KardiaAI library is integrated.
No, KardiaAI is an AI software library intended to assess ambulatory ECG rhythms from adult subjects, supporting data from various ambulatory ECG devices. The Zio XT system, however, is specifically designed for continuous, long-term ambulatory cardiac monitoring for up to 14 days.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.